Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences, Inc.

Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.

msh id	COM:ARCUSBIO
symbol	RCUS
name	Arcus Biosciences, Inc.
homepage url	https://www.arcusbio.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	577
crunchbase url	-
linkedin url	-
founders	-

market cap	1.27B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	6.47
growth score 28	6.92
growth score 90	10.56
growth score 365	87.14

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.17
growth cost of revenue	0.14
growth depreciation and amortization	-0.5
growth ebitda	-0.1
growth ebitda ratio	-0.06
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.13
growth gross profit	0.03
growth gross profit ratio	-0.01

COM:ARCUSBIO

Arcus Biosciences

Last Close

14.62

21/11 21:00

Market Cap

1.27B

Beta: -

Volume Today

676.15K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	457M
cost of revenue	457M
depreciation and amortization	8M
ebitda	-291M
ebitda ratio	-2.49
eps	-4.15
eps diluted	-4.15
operating expenses	457M
operating income	-340M
operating income ratio	-2.91

accounts receivables	15M
capital expenditure	-24M
cash at beginning of period	209M
cash at end of period	130M
inventory	-
working capital ttm	682M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-